FAQ

Metastatic Non-Squamous Non-Small Cell Lung Carcinoma

Known as: Metastatic Non-Squamous Non-Small Cell Lung Cancer 
A non-squamous non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2017
012320092017

Related topics

Related topics

14 relations
ChestEGFR Gene MutationEGFR geneEpithelial Cells
(More)

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
cancer cell
Lung
Neoplastic Cell
Chest
Epithelial Cells

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Dynamic human immune and tumour cells cross-talk in PDX-humanised mice warrants checkpoint inhibitor cancer immunotherapies assessment.
The concept of exploiting the host’s immune system to fight cancer relies on the concept of tumour immune surveillance, the… (More)
Is this relevant?
2017
2017
Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC
Delta-like ligand 4-Notch (DLL4-Notch) signaling contributes to the maintenance of chemotherapy-resistant cancer stem cells and… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2015
2015
Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer
Toxic epidermal necrolysis (TEN) is a rare acute life-threatening mucocutaneous disorder that is mostly drug-related (80%-95… (More)
Is this relevant?
2015
2015
Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first…
OBJECTIVES To compare the activity and tolerance of the consecutive administration of four active chemotherapeutic agents in… (More)
Is this relevant?
2014
2014
A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
INTRODUCTION Pemetrexed and erlotinib have been approved as second-line monotherapy for locally advanced or metastatic non-small… (More)
Is this relevant?
2014
2014
A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer
Background:This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in non… (More)
  • table 2
  • table 1
  • figure 1
  • table 3
Is this relevant?
2014
2014
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung…
BACKGROUND In the Iressa Pan-ASia Study (IPASS), gefitinib claimed improved progression-free survival (PFS) versus carboplatin… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2012
2012
Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non…
EGFR tyrosine kinase inhibitors (EGFR-TKIs) are recommended as first-line therapy in patients with advanced, recurrent, or… (More)
Is this relevant?
Review
2011
Review
2011
Revisiting cutaneous adverse reactions to pemetrexed.
Pemetrexed (Alimta®) is a multitargeted antifolate drug approved as a single agent or in combination with cisplatin for the… (More)
Is this relevant?
2009
2009
Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC).
e19023 Background: Bevacizumab (B), in addition to platinum-based chemotherapy, is indicated for 1st-line treatment of p with… (More)
Is this relevant?